Atlas Trials

Study to Assess the Safety of Amantadine Hydrochloride (HCl) Intravenous (IV) Solution (MR-301) in Patients With Severe Traumatic Brain Injury (TBI).

Clinical trial NCT06253923 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT06253923
Sponsor
SHINKEI Therapeutics, Inc
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Traumatic Brain Injury
Start date
2024-06-01
Primary completion
2025-07-31
Enrollment
45

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.